Albor A, Kaku S, Kulesz-Martin M. Wild-type and mutant forms of p53 activate human topoisomerase I: A possible mechanism for gain of function in mutants. Cancer Res., 58(10):2091-2094, 1998

Alhonen L, Karppinen A, Uusi-Oukari M, Vujcic S, Korhonen P, Halmekyto M, Kramer DL, Hines R, Janne J, Porter CW. Correlation of polyamine and growth responses to N1,N11-diethylnorspermine in primary fetal fibroblasts derived from transgenic mice overexpressing spermidine/spermine N1-acetyltransferase. J. Biol. Chem., 273(4):1964-1969, 1998

Cao SS, Black JD, Troutt AB, Rustum YM. Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model. Cancer Res., 58(15):3270-3274, 1998

Cao SS, Troutt AB, Rustum YM. Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer. Cancer Res., 58(8):1695-1699, 1998

Chiang SY, Azizkhan J, Beerman TA. Comparison of DNA-Binding Drugs as Inhibitors of E2F1- and Sp1-DNA Complexes and Associated Gene Expression. Biochemistry 37(9):3109-3115, 1998

 

Delon A, Levasseur LM, Greco WR, Faury P, Bouquet S, Couet W. Isobolographic assessment with a new quantitative approach of the convulsant interaction between pefloxacin and theophylline in rats. Pharmaceutical Res. 15:1069-1076, 1998

Dimitroff CJ, Sharma A, Bernacki RJ. Cancer metastasis: A search for therapeutic inhibition, Cancer Invest., 16(4):279-290, 1998

Ehrke MJ, Verstovsek S, Ujhazy P, Meer JM, Eppolito C, Maccubbin DL, Mihich E. Doxorubicin plus tumor necrosis factor-a combination treatments in EL4 lymphoma-bearing C57BL/6 mice. Cancer Immunology and Immunotherapy, 45(6):287-298, 1998

Ehrke MJ, Verstovsek S, Pocchiari SK, Krawczyk CM, Ujhazy P, Zaleskis G, Maccubbin, D.L, Meer JM, Mihich E. Thymic antitumor effectors in chemoimmunotherapy cured mice: phenotypic and functional characterization up to 20 months after initial tumor inoculation. Intl. J. Cancer 76:579-586, 1998

Faessel HM, Slocum HK, Jackson RC, Boritzki TJ, Rustum YM, Nair MG, Greco WR. Super in vitro synergy between inhibitors of dihydrofolate reductase and inhibitors of other folate-requiring enzymes: The critical role of polyglutamylation. Cancer Res., 58(14):3036-3050, 1998

Gangjee A, Elzein E, Queener SF, McGuire JJ. Synthesis and biological activities of tricyclic conformationally restricted tetrahydropyrido annulated furo[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases. J. Med. Chem., 41(9):1409-1416, 1998

Gimble J, Pighetti S, Lerner M, Wu X, Lightfoot S, Brackett D, Darcy K, Hollingsworth A. Expression of peroxisome proliferator-activated receptor mRNA in normal and tumorigenic rodent mammary glands. Biochem. Biophys. Res. Comm. 253: 813-817, 1998

Giordano A, Rustum YM, Wenner CW. Cell Cycle: Molecular Targets for Diagnosis and Therapy: Tumor Suppressor Genes and Cell Cycle Progression in Cancer. J. Cellular Biochem. 70:1-7, 1998

Goldberg B, Rattendi D, Lloyd D, Sufrin JR, Bacchi CJ. Effects of intermediates of methionine metabolism and nucleoside analogs on S-adenosylmethionine transport by Trypanosoma brucei brucei and a drug-resistant Trypanosoma brucei rhodesiense. Biochem.Pharmacol., 56:95-103, 1998

Hausheer FH, Kanter P, Cao S, Haridas K, Seetharamula P, Reddy D, Petluru P, Zhao M, Murali D, Saxe JD, Yao S, Martinez N, Zukowski A, Rustum YM. Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents. Sem. in Oncology 25:(5):584-599, 1998

Huang BG, Bobek M. Synthesis and in vitro antitumor activity of some amino-deoxy 7-hexofuranosylpyrrolo[2,3-d]pyrimidines. Carbohydr.Res., 308:319-328, 1998

 

Kramer DL, Black JD, Mett RJ, Bergeron RJ, Porter CW. Lysosomal sequestration of polyamine analogs in Chinese hamster ovary cells resistant to the S-adenosylmethionine decarboxylase inhibitor, CGP-48664. Cancer Research 58:3883-3890, 1998

Kramer DL, Vujcic S, Diegelman P, White C, Black JD, Porter CW. Polyamine analog-mediated cell cycle responses in human melanoma cells involves the p53, p21, Rb regulatory pathway. Biochem. Soc. Trans. 26:609-614, 1998

Levasseur LM, Delon A, Greco WR, Faury P, Bouquet S, Couet W. Development of a new quantitative approach for the isobolographic assessment of the convulsant interaction between pefloxacin and theophylline in rats. Pharm.Res., 15(7):1069-1076, 1998

Levasseur LM, Slocum HK, Rustum Y, Greco WR. Modeling of the time-dependency of in vitro drug cytotoxicity and resistance. Cancer Research, 58:5749-5761, 1998

Li ZR, Hromchak R, Mudipalli A, Bloch A. Tumor suppressor proteins as regulators of cell differentiation. Cancer Res. 58:4282-4287, 1998

Liu Y, Kisiel ND, Kulesz-Martin M. Identification of altered gene expression in a cloned keratinocyte model of carcinogenesis by RNA differential display, Carcinogenesis 19:101-104, 1998

Liu YG, Kulesz-Martin MF. Altered gene expression in a clonal epidermal cell model of carcinogenesis identified by RNA differential display. Carcinogenesis, 19(4):683-686, 1998

Macrae M, Kramer DL, Coffino P. Developmental effect of polyamine depletion in C. elegans. Biochemical Journal 333:309-315, 1998

Masso-Welch P, Verstovsek G, Darcy K, Tagliarino C, Ip M. Protein Kinase C eta upregulation and secretion during postnatal rat mammary gland differentiation. Eur. J. Cell Biology, 77:48-59, 1998

McGuire JJ, Russell CA. Folylpolyglutamate synthetase expression in antifolate-sensitive and -resistant human cell lines. Oncology Research 10:193-200, 1998

Mi Z, Kramer DL, Miller J, Bergeron RJ, Bernacki RJ, Porter CW. Human prostatic carcinoma cell lines display altered regulation of polyamine transport in response to polyamine analogs and inhibitors. The Prostate 34:51-60, 1998

Mihich E, Croce C. Editors, The Biology of Tumors. Ninth Annual Pezcoller Symposia, Plenum Press, NY, 1998

Minderman H, Cao S, Rustum YM. Rational design of Irinotecan administration based on preclinical models. Oncology, 12(8):22-30, 1998

Ojima I, Bounaud PY, Bernacki RJ. New weapons in the fight against cancer. Chemtech 28(6):31-36, 1998

Ojima I, Bounaud PY, Takeuchi C, Pera P, Bernacki RJ. New taxanes as highly efficient reversal agents for multi-drug resistance in cancer cells, Bioorg. Med. Chem. Lett., 8(2):189-194, 1998

Ojima I, Lin SN, Chakravarty S, Fenoglio I, Park YH, Sun CM, Appendino G, Pera P, Veith JM, Bernacki RJ. Syntheses and structure-activity relationships of novel nor-seco taxoids. J.Org.Chem., 63(5):1637-1645, 1998

Przybyszewski J, Box HC, Kulesz-Martin M. Induction of reactive oxygen species without 8-hydroxydeoxyguanosine formation in DNA of initiated mouse keratinocytes treated with 12-O-tetradecanoylphorbol-13-acetate. Carcinogenesis, 19(8):1467-1474, 1998

Raghavan D, Rustum YM. Introduction. Eur. J. Cancer [A], 34(10):1492, 1998

Rustum YM. Colon Cancer: New Drug Options Improve on 5-FU. J. Natl. Cancer Institute 90(13), 963-965, 1998

Rustum YM, Cao S. Metabolic modulation of 5-Fluorouracil by high dose leucovorin; preclinical rationale and clinical efficacy. In: Management of Colorectal Cancer, H. Bleiberg, P. Rougier and H-J. Wilke, eds., Martin Dunitz Publishers, New York, 1998, pp. 229-237

Rustum YM, Cao S, Zhang Z. Rationale for Treatment Design: Biochemical Modulation of 5-fluorouracil by Leucovorin. The Cancer Journal from Scientific America, 4(1):12-18, 1998

Todovov IT, Werness BA, Wang HQ, Buddharaju LN, Todorova PD, Slocum HK, Brooks JSJ, Huberman JA. HsMCM2/BM28: A novel proliferation marker for human tumors and normal tissues, Lab. Invest., 78(1):73-78, 1998

Toth K, Vaughan M, Schwartz G, Winston J, Skenderis B, Slocum H, Rustum YM. Expression of the MRP and MDR1 multidrug resistance gene products in 160 untreated human carcinomas studied by immunohistochemical methods in formalin-paraffin sections. Intl. J. Surgical Path., 6(3):145-154, 1998

Tsukamoto T, Haile WH, McGuire JJ, Coward JK. Mechanism-based inhibition of human folylpolyglutamate synthetase: Design, synthesis, and biochemical characterization of a phosphapeptide mimic of the tetrahedral intermediate. Arch.Biochem.Biophys., 355(1):109-118, 1998

VanLaar JAM, Rustum YM, Ackland SP, VanGroeningen CJ, Peters GJ. Comparison of 5-fluoro-2’-deoxyuridine to 5-fluorouracil; and their role in the treatment of colorectal cancer. Europ. J. Cancer, 34(3):296-306, 1998

Verstovsek G, Byrd A, Frey MR, Petrelli NJ, Black JD. Colonocyte differentiation is associated with increased expression and altered distribution of PKC isozymes. Gastroenterology 115: 75-85, 1998

Voigt W, Matsui S, Yin M, Silver L, Burhans W, Rustum,YM. Topoisomerase-I Inhibitor SN-38 can induce DNA damage and chromosomal aberrations independent from DNA synthesis. Anticancer Res., 18:3499-3506, 1998

Warren AJ, Maccubbin AE, Hamilton JW. Detection of mitomycin C-DNA adducts in vivo by 32P-postlabeling: Time course for formation and removal of adducts and biochemical modulation. Cancer Res. 58:453-461, 1998

Webb MS, Logan P, Kanter PM, St-Onge G, Gelmon K, Harasym T, Mayer LD, Bally MB. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer. Cancer Chemother.Pharmacol., 42(6):461-470, 1998

Yin MB, Guo B, Voigt W, Vanhoefer U, Gibbs JF, Skenderis BS, Frank C, Wrzosek C, Rustum YM. Novel Cellular Determinants for Reversal of Multidrug Resistance in Cells Expressing P170-Glycoprotein. Biochimica et Biophysica Acta, 265-276, 1998